Form 4: Stryker CEO Lobo Exercises Options, Acquires New Grant

Sentiment:

Insider Transaction Report 6 February 2026 4:18 PM

Stryker Corp's Chair and CEO, Kevin Lobo, reported exercising stock options, acquiring new options, and a related stock disposition for tax purposes.

Summary

Kevin Lobo, Chair and CEO of Stryker Corp, exercised 206,955 employee stock options at a price of $96.64 per share on February 6, 2026.
Concurrently, 132,410 shares of common stock were disposed of at $362.42 per share, likely for tax withholding related to the option exercise.
Following these transactions, Lobo directly holds 196,940 shares of common stock and indirectly holds 721 shares in a 401K.
The direct holdings include 2,782 shares acquired through Stryker Corporation's Employee Stock Purchase Plan as of December 31, 2025.
Lobo was granted new employee stock options on February 4, 2026, for 58,206 shares at an exercise price of $360.82, exercisable 20% annually over five years, expiring February 3, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine insider filing reflecting standard executive compensation practices. The exercise of options and grant of new ones indicate ongoing alignment of management incentives with company performance.

Positives

Exercise of long-held options indicates a realization of value by the CEO.
Grant of new stock options aligns the CEO's long-term incentives with shareholder interests.
The exercise price of the new options ($360.82) is close to the market price at which shares were disposed ($362.42), suggesting the company's stock is performing well.

Negatives

A significant portion of shares (132,410) were disposed of, likely for tax purposes, reducing direct beneficial ownership.

Future Outlook

The filing does not contain specific forward-looking statements or guidance, as it primarily reports past insider transactions and option grants.

Industry Context

StockSavvy.ai notes that insider transactions, particularly option exercises and grants, are common forms of executive compensation in the medical technology industry. The grant of new options to the CEO, Kevin Lobo, aligns his incentives with the long-term performance of Stryker, a common practice among industry leaders like Medtronic (MDT) and Johnson & Johnson (JNJ) to retain top talent and drive shareholder value.

Comparison to Industry Standards

Executive compensation structures in the medical device sector frequently include significant equity components, such as stock options and restricted stock units, similar to those seen at Stryker.
For instance, Medtronic's (MDT) executive compensation packages often feature performance-based equity awards tied to financial metrics and shareholder returns.
Johnson & Johnson (JNJ) also utilizes long-term incentive plans with stock options and performance share units to incentivize leadership.
The exercise of options and subsequent tax-related sales by Stryker's CEO are standard practices for executives realizing value from such plans across the industry.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Power of Attorney Grant	Kevin A. Lobo granted a Power of Attorney to five individuals (Austin Y. Ke, Jessica R. Kennedy, Jessica M. Herron, Garrett Packer, and Stephanie M. Swan) to handle his SEC filings (Forms 3, 4, 5, 13D, 13G, 144) and EDGAR account administration.	08/28/2025	Enhances efficiency and compliance for insider reporting requirements by delegating administrative tasks to designated attorneys-in-fact.

Related Party Transactions

Acquisition of 2,782 shares of Stryker Common Stock through Stryker Corporation's Employee Stock Purchase Plan (ESPP) as of December 31, 2025.

Stakeholder Impact

Shareholders: The exercise of options and grant of new options to the CEO demonstrate ongoing alignment of executive incentives with shareholder value creation.
Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates a broader program for employee equity participation.

Next Steps

The newly granted employee stock options will become exercisable as to 20% on each of the first five anniversaries of the grant date (February 4, 2026).

Key Dates

Date	Description
02/10/2016	Grant date of employee stock option that was exercised.
08/28/2025	Date Power of Attorney was executed by Kevin A. Lobo.
12/31/2025	Date of latest available statement for reporting person's ESPP holdings.
02/04/2026	Date of earliest transaction reported (grant of new options).
02/04/2026	Grant date of new employee stock option for 58,206 shares.
02/06/2026	Date of option exercise and stock disposition.
02/06/2026	Signature date of reporting person's attorney-in-fact.
02/09/2026	Expiration date of the exercised employee stock option.
02/03/2036	Expiration date of the newly granted employee stock option.

Recommendation

hold

This Form 4 filing details routine insider transactions, including the exercise of stock options and the grant of new equity awards to the CEO. Such activities are standard components of executive compensation and do not typically signal a fundamental change in the company's prospects or warrant a change in investment thesis. The transactions reflect the realization of value from past compensation and the establishment of new long-term incentives. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than these specific insider filings.

Keywords

Stryker, SYK, Kevin Lobo, Form 4, Insider Trading, Stock Options, Equity Compensation, CEO, Director, Share Ownership, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.